Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016.
GBD 2016 Causes of Death Collaborators
https://pubmed.ncbi.nlm.nih.gov/28919116Actively Recruiting
Age: 18Years - 75Years
All Genders
ID04037995
Real World Study of End-stage Liver Disease in China
Led by Huashan Hospital · Updated on 2019-07-30
10000
Participants Needed
1
Research Sites
469 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to explore the current situation of end-stage liver disease in China and improve the diagnosis and treatment of liver cirrhosis and its complications. It focuses on liver cirrhosis caused by various conditions such as hepatitis, alcohol use, non-alcoholic causes, and schistosomiasis. The study also covers late-stage liver disease marked by severe liver function impairment, including chronic and acute liver failure, acute decompensation of cirrhosis, chronic liver failure, and advanced liver cancer. Understanding the epidemiology and treatment of these conditions is important due to their serious complications and high mortality rates. The study is a single-center, prospective, observational real-world investigation without any intervention treatments. It examines the current diagnosis and treatment practices for cirrhosis and end-stage liver disease in China, aiming to gather data on treatment efficacy, safety, and economic benefits. The goal is to identify optimized treatment options that may improve patient outcomes and reduce mortality. Participants will be observed over a three-year period with regular follow-ups to monitor survival and major health events. Researchers will collect clinical data to analyze outcomes such as patient death and significant complications during the follow-up. The study will provide valuable evidence to guide future management and treatment of cirrhosis and end-stage liver disease in China.
CONDITIONS
Brief Title
Real World Study of End-stage Liver Disease in China
Who Can Participate
Age: 18Years - 75Years
All Genders
Eligibility Criteria
You may qualify if you...
- Patient has given informed consent.
- Diagnosed with acute decompensation of cirrhosis, chronic or acute liver failure, chronic liver failure, or stage III-IV hepatocellular carcinoma.
- Age between 18 and 75 years.
You will not qualify if you...
- Positive for HIV antibody or diagnosed with AIDS.
- History of serious psychiatric illness, including major depression, psychosis, suicide attempts, hospitalization for mental illness, or disability due to mental illness.
- Serious diseases affecting heart, lung, kidney, brain, blood, or other important organs.
- Presence of other malignant tumors except those cured.
- Pregnant, breastfeeding, or women of childbearing potential planning to conceive.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Surveillance
Duration - Up to 3 years
Participants who undergo routine care are observed to investigate the diagnosis, treatment, and outcomes of end-stage liver disease in a real-world setting in China.
Periodic visits as per routine clinical care
Trial Site Locations
Total: 1 location
1
HuaShan Hospital
Shanghai, Shanghai Municipality, China, 200040
Actively Recruiting
Loading map...
Research Team
J
Jingwen Ai, Doctor
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here